Lack of effect of sibutramine an the efficacy of oral contraceptive steroids in healthy women

International Journal of Pharmaceutical Medicine

Volumn 11, Issue 2, 1997, Pages 71-76

  Back, David J ^a   Fearn, Rachael ^b   Oliver, Stuart ^c   Stott, David A ^b   Wynne, Ronan D ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

^c Besselaar Clinical Research Unit   (United Kingdom)

Author keywords

Appetite depressants; Contraceptives; Controlled clinical trials; Drug interactions; Hormonal; Obesity; Oral

Indexed keywords

ANOREXIGENIC AGENT; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETONOGESTREL; FOLLITROPIN; LEVONORGESTREL; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; SIBUTRAMINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; FEMALE; FOLLITROPIN BLOOD LEVEL; HEADACHE; HUMAN; HUMAN EXPERIMENT; LUTEINIZING HORMONE BLOOD LEVEL; NAUSEA; NORMAL HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; SINGLE BLIND PROCEDURE; VOMITING;

EID: 0030867789     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Office of Population Censuses and Surveys. Health survey for England, 1991. London, HMSO.
2. Bray GA. Overweight is risking fate. Definition, classification, prevalence and risks. Annals of the New York Academy of Science 1987; 499: 14-28.
3. Simopoulos AP. Characteristics of obesity: an overview. Annals of the New York Academy of Science 1987; 499: 4-13.
4. Bjorntorp P. The associations between obesity, adipose tissue distribution and disease. Acta Medica Scandinavica 1988; 723 (Suppl): 121-134.
5. Negri E, Pagano R, Decarli A, La Vecchia C. Bodyweight and the prevalence of chronic diseases. Journal of Epidemiology and Community Health 1988; 42: 24-29.
6. Heraief E. The contribution of epidemiology to the definition of obesity and its risk factors. Therapeutische Umschau 1989; 46: 275-280.
7. Waaler HT. Hazards of obesity: the Norwegian experience. Acta Medica Scandinavica 1988; 723 (Suppl): 17-21.
8. Higgins M, Kannel W, Garrison R, Pinsky J, Stokes J. Hazards of obesity: the Framingham experience. Acta Medica Scandinavica 1988; 723 (Suppl): 23-36.
9. Rissanen A, Heliovaara M, Knekt P, Aromaa A, Reunanen A, Maatela J. Weight and mortality in Finnish men. Journal of Clinical Epidemiology 1989; 42: 781-789.
10. Garner DM, Wooley SC. Confronting the failure of behavioral and dietary treatments of obesity. Clinical Psychology Review 1991; 6: 58-137.
11. Halford JCG, Heal DJ, Blundell JE. Effects in the rat of sibutramine on food intake and the behavioural satiety sequence. British Journal of Pharmacology 1995; 114: 387P.
12. Connoley IP, Heal DJ, Stock MJ. A study in rats of the effects of sibutramine on food intake and thermogenesis. British Journal of Pharmacology 1995; 114: 388P.
13. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: a dose-ranging, efficacy study. Clinical Pharmacology and Therapeutics 1991; 50: 330-337.
14. Drouin P, Hanotin C, Courcier S, Leutenegger E. A dose-ranging study: efficacy and tolerability of sibutramine in weight loss. International Journal of Obesity 1994; 18 (Suppl 2): 60.
15. Jones SP, Newman BM, Romanec FM. Sibutramine hydrochloride: weight loss in overweight subjects. International Journal of Obesity 1994; 18 (Suppl 2): 61.
16. Kelly F, Wade AG, Jones S, Johnson SG. Sibutramine hydrochloride vs dexfenfluramine: weight loss in obese subjects. International Journal of Obesity 1994; 18(Suppl 2): 61.
17. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain A, Kaiser PE, Mendels J, Ryan D, Schwartz SL. Sibutramine dose response and long-term efficacy in weight loss, a double-blind study. International Journal of Obesity 1994; 18 (Suppl 2): 60.
18. Mendels J, Blackburn GL, Bray GA, Ferguson JM, Greenway FL, Jain A, Kaiser PE, Ryan D, Schwartz SL. Sibutramine and long-term weight loss: % of patients losing 5 and 10% of baseline weight. International Journal of Obesity 1994; 18 (Suppl 2): 61.
19. Jones SP, Smith IG, Kelly F, Gray JA. Long term weight loss with sibutramine. International Journal of Obesity 1995; 19 (Suppl 2): 41.
20. Israel R, Mishell DR, Stone SC, Thorneycroft IH, Moyer DL. Single luteal phase serum progesterone assay as an indicator of ovulation. American Journal of Obstetrics and Gynecology 1992; 112: 1043-1046.
21. Smith MA, Youngkin EQ. Current perspectives on combination oral contraceptives. Clinical Pharmacy 1984; 3: 485-496.
22. Back DJ, Tjia J, Martin C, Millar E, Mant T, Morrison P, Orme M. The lack of interaction between temafloxacin and combined oral contraceptive steroids. Contraception 1991; 43: 317-323.
23. Back DJ, Tjia J, Martin C, Millar E, Salmon P, Orme M. The interaction between clarithromycin and combined oral-contraceptive steroids. Journal of Pharmaceutical Medicine 1991; 2: 81-87.
24. Back DJ, Breckenridge AM, MacIver M, Orme M, Staiger Ch, Thomas E, Tjia J. The interaction between ampicillin and oral contraceptive steroids in women. British Journal of Clinical Pharmacology 1982; 13: 281P.
25. Neeley JL, Abate M, Swinker M, D'Angio R. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. Obstetrics and Gynecology 1991; 77: 416-420.
26. Metropolitan Life Assurance Company. Data tape, HANES I-Anthropometry, goniometry, skeletal age, bone density and cortical thickness, ages 1-74, National Health and Nutrition Examination Survey, 1971-1975. National Centre for Health Statistics, 1983.
27. Back DJ, Breckenridge AM, Crawford PE, MacIver M, Orme M, Rowe PH, Watts MJ. An investigation of the pharmacokinetics of ethinyloestradiol in women using radioimmunoassay. Contraception 1979; 20: 263-273.
28. Back DJ, Bates M, Breckenridge AM, Hall MJ, MacIver M, Orme M, Park BK, Rowe PH. The pharmacokinetics of levonorgestrel and ethinyloestradiol in women - studies with Ovran and Ovranette. Contraception 1981; 23: 229-239.
29. Shaw MA, Back DJ, Cowie AM, Orme M. A non-chromatographic radioimmunoassay for 3-oxo desogestrel. J Steroid Biochemestry 1984; 22: 111-113.
30. Wide L, Nillius SJ, Gremzell C, Roos P. Radioimmunosorbent assay of follicle stimulating hormone and luteinizing hormone in serum and urine from men and women. Acta Endocrinologica 1973; 174 (Suppl): 1-58.
31. Meyer B, Mhller F, Wessels P, Maree J. A model to detect interactions between roxithromycin and oral contraceptives. Clinical Pharmacology and Therapeutics 1990; 47: 671-674.
32. Goldzieher JW. The hypothalamo-pituitary-ovarian system. In: Pharmacology of the Contraceptive Steroids 1994; JW Goldzieher (ed.), Raven Press Ltd, New York, p.185.